>>172368, >>172369, >>172370, >>172371, >>172372, >>172373, >>172374, >>172375, >>172376, >>172377, >>172378, >>172379, >>172380, >>172381, >>172382, >>172383, >>172384, >>172385, >>172386, >>172387, >>172388, >>172389, >>172390, >>172391, >>172392, >>172393, >>172394, >>172395, >>172396, >>172397, >>172398, >>172399, >>172400, >>172401, >>172402, >>172403, >>172404, >>172405, >>172406, >>172407, >>172408, >>172409, >>172410, >>172411, >>172412, >>172413, >>172414, >>172415, >>172416, >>172417, >>172418, >>172419, >>172420, >>172421, >>172422, >>172423, >>172424, >>172425, >>172426, >>172427, >>172428, >>172429, >>172430, >>172431
The White House @WhiteHouse - 5 Trump Moves From 2025 You Didn’t Hear About From Legacy Media
https://www.dailysignal.com/2025/12/28/five-trump-moves-from-2025-you-didnt-hear-about-from-legacy-media/
https://x.com/WhiteHouse/status/2005664070012412354

The White House @WhiteHouse - President Donald J. Trump meets with Ukrainian President @ZelenskyyUa at Mar-a-Lago. 🇺🇸🇺🇦
https://x.com/WhiteHouse/status/2005631250892292281

William Makis (McGill Medicine) @MakisMedicine - NEW ARTICLE: ALZHEIMER'S DISEASE - Boswellia Serrata - 2022 (Canada-Iran) Clinical Trial with 85 patients with mild to moderate Alzheimer's disease took Boswellia for 6 months and saw significant improvements!
To summarize: 43 Alzheimer's patients took Boswellia 1200mg/day (split into 3 doses) for 6 months (and the other 42 took placebo).
The Boswellia group showed:
Thinking and memory improved (MMSE)
Overall dementia severity improved, placebo worsened
Behavior and mood (agitation, anxiety): meaningful reduction in symptoms
Blood Tests: boswellia lowered levels of several inflammation-causing proteins (IL-6, TNF-α, and IL-1α) that are linked to Alzheimer’s progression
No serious side effects reported
“Bottom line in simple terms: In this small study, taking Boswellia for 6 months appeared to slow cognitive decline, improve dementia symptoms, reduce mood/behavior issues, lower brain-harming inflammation, and shift a key Alzheimer’s blood marker in a good direction—all compared to placebo, with no major safety problems.”